Efficacy and Safety of HAT1 Compared to Calcipotriol in Patients With Mild to Moderate Chronic Plaque Psoriasis
Status:
Completed
Trial end date:
2016-09-05
Target enrollment:
Participant gender:
Summary
Psoriasis, the most prevalent autoimmune disease in the U.S., manifests with plaque type
psoriasis vulgaris with lesions localized to the scalp, postauricular region, face, diaper
area, elbows, and knees. Inadequately controlled disease is common and a significant cause of
extensive psychological and clinical morbidity in children. In addition, the safety and
tolerability issues of common treatments for psoriasis including topical corticosteroids,
calcipotriol, oral cytotoxic drugs, and biologic agents are especially problematic in
patients that limit their use. Identification of therapies with high efficacy and safety
profiles suitable for patients with psoriasis is therefore an area of critical unmet need.
Haus Bioceuticals has developed a topical treatment for psoriasis denoted HAT1 (based on
ingredients that have established clinical benefit), and have demonstrated that HAT1 is safe
and profoundly effective in the treatment of psoriasis. This study is aimed to further
evaluate the efficacy and safety of HAT1 compared to commonly used calcipotriol in patients
with mild to moderate chronic plaque psoriasis.